Jefferies analyst Glen Santangelo upgrades Teva Pharmaceutical Indus (NYSE:TEVA) from Hold to Buy and raises the price target from $10 to $14.
Jefferies Upgrades Teva Pharmaceutical Indus to Buy, Raises Price Target to $14
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.